Steven R. Martin Net Worth

Mr. Steven R. Martin biography

Steven R. Martin is the Chief Financial Officer at Armata Pharmaceuticals Inc.

What is the salary of Mr Martin?

As the Chief Financial Officer of Armata Pharmaceuticals Inc, the total compensation of Mr Martin at Armata Pharmaceuticals Inc is $490,000. There are 2 executives at Armata Pharmaceuticals Inc getting paid more, with Todd R. Patrick MBA having the highest compensation of $773,250.

How old is Mr Martin?

Mr Martin is 60, he's been the Chief Financial Officer of Armata Pharmaceuticals Inc since . There are 2 older and 4 younger executives at Armata Pharmaceuticals Inc. The oldest executive at Armata Pharmaceuticals Inc is Duane Alfred Morris BA, 71, who is the VP of Operations.

What's Mr Martin's mailing address?

Steven's mailing address filed with the SEC is C/O ARMATA PHARMACEUTICALS, INC., 4503 GLENCOE AVENUE, MARINA DEL REY, CA, 90292.

Insiders trading at Armata Pharmaceuticals Inc

Over the last 6 years, insiders at Armata Pharmaceuticals Inc have traded over $0 worth of Armata Pharmaceuticals Inc stock and bought 24,083,630 units worth $91,149,692 . The most active insiders traders include Inc.Innoviva Strategic Oppo..., Inc. Innoviva, és Michael S Perry. On average, Armata Pharmaceuticals Inc executives and independent directors trade stock every 122 days with the average trade being worth of $9,151,779. The most recent stock trade was executed by Inc.Innoviva Strategic Oppo... on 31 March 2022, trading 5,385,208 units of ARMP stock currently worth $26,926,040.

What does Armata Pharmaceuticals Inc do?

c3 jian is a well-capitalized, private, los angeles based biotechnology company advancing novel compounds that target unmet medical/dental needs related primarily to oral healthcare. the company's lead compound is a unique peptide drug against dental caries (i.e. tooth decay). the company’s lead compound started fda-regulated phase ii human clinical trials in early 2014. c3 jian's platform technology has also yielded peptides that can affect calcification processes, including not only tooth sensitivity but possibly hair and nail growth as well. the company has recently moved its operations to a new facility in marina del rey. the company was founded based on technology created in the laboratory of dr. wenyuan shi, chair of the department of oral biology at the university of california, los angeles school of dentistry. for more information about the company and to explore career opportunities at c3 jian please visit our webpage at www.c3-jian.com

Armata Pharmaceuticals Inc executives and stock owners

Armata Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Todd R. Patrick MBA,
  Advisor & Director
• Dr. Brian Varnum Ph.D.,
  CEO & Director
• Steven R. Martin,
  Chief Financial Officer
• Robin Kramer,
  Director
• Mina Pastagia,
  Vice President - Clinical Development
• Sarah Schlesinger,
  Director
• Odysseas Kostas,
  Director
• Todd Peterson,
  Director
• Heather Jones,
  Medical Director
• Joseph Patti,
  Director
• Richard Bastiani,
  Director
• Duane Morris,
  Vice President - Operations
• Igor Bilinsky,
  Chief Operating Officer, Senior Vice President
• Steven Martin,
  Chief Financial Officer
• Todd Patrick,
  Chief Executive Officer, Director
• Brian Varnum,
  President, Chief Development Officer
• Erin Butler,
  VP of Fin. & Admin.
• Dr. Mina Pastagia M.D., MS,
  Sr. VP of Clinical Devel.
• Duane Alfred Morris BA,
  VP of Operations
• Dr. Wenyuan Shi Ph.D.,
  Co-Founder & Founding Scientist
• Deborah Birx,
  Chief Executive Officer
• Richard Rychlik,
  Corporate Controller and PFO
• Inc. Innoviva,,
  10% owner
• Richard Bear,
  Director
• Michael S Perry,
  Director
• H Stewart Parker,
  Director
• Jeremy Curnock Cook,
  Director
• Inc.Innoviva Strategic Oppo...,
  
• Jules Haimovitz,
  Director